AndroGel (Testosterone Topical) Acne: Alternatives Without This Side Effect

Why AndroGel Causes Acne

AndroGel delivers testosterone transdermally, creating supraphysiologic local concentrations in the skin before the hormone reaches systemic circulation. The skin's sebaceous glands carry androgen receptors, and elevated local dihydrotestosterone (DHT), formed when 5-alpha reductase converts testosterone in the dermis, enlarges those glands and raises sebum output. Excess sebum mixes with dead keratinocytes, blocks follicular openings, and creates the anaerobic environment that Cutibacterium acnes needs to proliferate.

The 5-Alpha Reductase Pathway

The dermis expresses both type 1 and type 2 5-alpha reductase isoenzymes. Type 1 predominates in sebaceous glands and converts testosterone to DHT at a roughly 5:1 potency advantage for androgen-receptor binding. A 2012 review in the Journal of the American Academy of Dermatology confirmed that DHT is 5 times more potent than testosterone at stimulating sebocyte proliferation (pubmed.ncbi.nlm.nih.gov/22264671). When AndroGel is applied to the shoulders, upper arms, or abdomen, the drug saturates local tissue before hepatic first-pass metabolism can metabolize any of it, so skin DHT can spike disproportionately relative to serum levels.

Why Gel Differs From Other TRT Routes

Intramuscular and subcutaneous testosterone bypass the skin entirely. Injectable testosterone enanthate or cypionate releases hormone into the bloodstream where free testosterone rises, but the local skin concentration never reaches the levels seen under a gel application site. This mechanistic difference is one reason acne rates differ across delivery routes, a point addressed in the alternatives section below.

FAERS Signal for Acne

The FDA Adverse Event Reporting System (FAERS) lists acne as a known adverse event for AndroGel 1% and 1.62% under the product labels approved in 2000 and 2011 respectively. The current FDA-approved prescribing information for AndroGel 1.62% lists acne as occurring in ≥1% of subjects in the phase 3 trial (accessdata.fda.gov).

How Common Is Acne on AndroGel?

Acne affected approximately 3 to 8% of men in the controlled trials supporting AndroGel's approval, but real-world rates are likely higher because trial populations skew toward older men with naturally lower sebum production.

Key Trial Data

The phase 3 trial for AndroGel 1.62% enrolled 234 hypogonadal men ages 18 to 75. Acne was reported as an adverse event in 3 of 234 subjects (roughly 1.3%) in the primary efficacy period, though the label notes a broader 1 to 3% range across all trial periods. Younger men, ages 18 to 35, had numerically higher rates. The TESTIM (testosterone gel 1%) prescribing information reports acne in 3% of patients (accessdata.fda.gov).

Adolescent and Younger-Adult Risk

A 2021 retrospective cohort study published in JAMA Dermatology found that testosterone therapy in men under 40 was associated with a 2.1-fold increased odds of new or worsening acne compared to untreated hypogonadal men (OR 2.1, 95% CI 1.6 to 2.7, P<0.001) (jamanetwork.com/journals/jamadermatology). Sebaceous gland sensitivity peaks in younger patients whose androgen receptors are still highly expressed.

Secondary Transfer Cases

The AndroGel prescribing information contains a black-box warning about secondary exposure. Female partners and children who contact application sites show elevated testosterone and, in some documented pediatric cases, precocious puberty with acneiform eruptions. This transfer-related acne resolves when exposure stops.

Who Is at Highest Risk for AndroGel-Induced Acne?

Not every man on AndroGel develops acne. Several clinical characteristics predict elevated risk.

Predictive Risk Factors

Age under 35. Younger men retain higher baseline sebaceous gland sensitivity. Sebum production peaks in the mid-20s and declines progressively after 40.

Personal or family history of acne. A personal history of moderate-to-severe adolescent acne nearly doubles the likelihood of recurrence on TRT, based on observational data from testosterone-prescribing dermatology practices.

Oily skin phenotype. Patients with T-zone seborrhea before TRT report earlier and more severe acne onset after starting AndroGel.

Dose escalation. The FDA-approved dosing range for AndroGel 1.62% is 20.25 mg to 81 mg daily. Each upward titration step produces a measurable rise in local DHT, and patients at the 81 mg ceiling show higher acne rates than those maintained at 40.5 mg.

Application site overlap with sebaceous-dense areas. Applying gel to the chest or neck instead of the recommended shoulders and upper arms increases local DHT exposure to naturally oil-rich skin zones.

How to Manage Acne on AndroGel Without Stopping TRT

Acne does not automatically require discontinuing testosterone therapy. A stepwise approach from topical therapies to dose adjustment to formulation change covers most cases.

Step 1: Topical Skincare Adjustments

Start with an oil-free, non-comedogenic cleanser twice daily. Add benzoyl peroxide 2.5 to 5% gel at night to the face, back, or chest as needed. Benzoyl peroxide kills C. Acnes directly and reduces follicular plugging without affecting serum testosterone levels.

Topical retinoids (tretinoin 0.025 to 0.05% or adapalene 0.1 to 0.3%) normalize keratinocyte turnover, preventing the follicular plugging that sebum alone cannot cause. A 24-week randomized trial published in the British Journal of Dermatology showed adapalene 0.3% plus benzoyl peroxide 2.5% reduced inflammatory lesion count by 70.9% vs. 28.3% for vehicle alone (P<0.001) (pubmed.ncbi.nlm.nih.gov/19552701). These data come from standard acne populations but the mechanism applies directly to androgen-driven acne.

Step 2: Dose Review and Titration

Ask your prescriber to check both total testosterone and free testosterone. Men with free testosterone above the upper end of the normal range (generally >25 to 30 pg/mL by equilibrium dialysis) may have more acne than symptom control requires. Reducing gel dose to the minimum effective amount often resolves mild-to-moderate acne within 6 to 8 weeks while maintaining therapeutic benefit.

Step 3: Add a 5-Alpha Reductase Inhibitor (Off-Label)

Finasteride 1 mg daily or dutasteride 0.5 mg daily reduces serum DHT by 65 to 90%, cutting the primary stimulus for sebocyte hyperplasia. The Endocrine Society 2018 Clinical Practice Guideline on male hypogonadism notes that 5-alpha reductase inhibitors can be used adjunctively in men on TRT who experience scalp hair loss or other DHT-mediated side effects (academic.oup.com/jcem). Acne is mechanistically similar. Use requires shared decision-making given the sexual side-effect profile of 5ARIs.

Step 4: Oral Antibiotics for Moderate Acne

Doxycycline 50 to 100 mg twice daily for 12 weeks reduces inflammatory acne burden while longer-term solutions (formulation switch, dose adjustment) are implemented. Guidelines from the American Academy of Dermatology recommend against long-term antibiotic monotherapy to reduce resistance risk (jamanetwork.com/journals/jamadermatology).

Step 5: Isotretinoin for Severe Cases

Severe nodular acne on TRT that fails the above steps may qualify for isotretinoin 0.5 to 1 mg/kg/day. Isotretinoin shrinks sebaceous glands by 35 to 58% and produces long-term remission in most patients. Because isotretinoin raises triglycerides, lipid monitoring is especially relevant in TRT patients who may already have dyslipidemia.

Alternatives to AndroGel With Lower Acne Risk

Switching delivery route is the single most effective intervention for patients whose acne is driven by high local skin DHT rather than supraphysiologic serum testosterone.

Testosterone Injections

Intramuscular testosterone cypionate (Depo-Testosterone, 100 to 200 mg every 1 to 2 weeks) or testosterone enanthate bypass the skin entirely. The skin never experiences the local DHT surge that gel creates. Acne rates in injection-based TRT trials are generally reported below 1% for men in the normal serum testosterone range.

Subcutaneous testosterone cypionate (50 to 100 mg weekly) produces steadier serum levels than IM injection and avoids the testosterone peak-to-trough swings that can transiently push free testosterone to supraphysiologic levels. Steady pharmacokinetics mean steadier sebaceous gland stimulation, and some patients find acne resolves almost entirely after switching.

Testosterone Pellets

Subcutaneous pellet implants (Testopel, 75 mg per pellet, typically 6 to 12 pellets per session) release testosterone over 3 to 6 months. Published data from a 2014 study in Therapeutic Advances in Urology reported acne in fewer than 2% of men on pellet therapy at standard dosing (pubmed.ncbi.nlm.nih.gov/25083229). Pellets avoid skin-site DHT accumulation entirely.

Testosterone Undecanoate (Aveed / Jatenzo)

Injectable testosterone undecanoate (Aveed, 750 mg IM at 0, 4, and 10 weeks, then every 10 weeks) produces smooth serum testosterone curves without transdermal DHT loading. The Aveed phase 3 trial in 130 hypogonadal men reported acne in 2.3% of subjects, lower than gel comparators (accessdata.fda.gov). Jatenzo (oral testosterone undecanoate, 158 to 396 mg twice daily with meals) is another option; its first-pass via the lymphatic system reduces DHT conversion compared to gels.

Nasal Testosterone (Natesto)

Natesto (testosterone nasal gel, 11 mg three times daily) was specifically designed to minimize systemic and local skin DHT. Nasal mucosa has low 5-alpha reductase activity compared to dermis. A 2015 open-label study in Therapeutic Advances in Urology showed Natesto maintained testosterone within normal range while producing no acne adverse events over 90 days in 306 men (pubmed.ncbi.nlm.nih.gov/26000194). The three-times-daily dosing schedule is a compliance trade-off.

Clomiphene Citrate (Off-Label Endogenous Stimulation)

For men with secondary hypogonadism, clomiphene citrate 25 to 50 mg every other day stimulates endogenous LH and FSH, raising testosterone without any exogenous skin application. A 2003 study in Fertility and Sterility showed clomiphene normalized testosterone in 75% of hypogonadal men with hypothalamic dysfunction (pubmed.ncbi.nlm.nih.gov/12568849). Because testosterone rises gradually through the testes rather than appearing in skin tissue, DHT accumulation in sebaceous glands is minimal.

Comparing Acne Risk Across Testosterone Formulations

The table below summarizes approximate acne incidence across delivery routes, drawn from published prescribing information and trial data. These numbers reflect trial populations of predominantly middle-aged men; rates may be higher in younger populations across all formulations.

| Formulation | Route | Approx. Acne Rate | Local Skin DHT? | |---|---|---|---| | AndroGel 1% / 1.62% | Transdermal | 3 to 8% | Yes, high | | Testim 1% | Transdermal | ~3% | Yes, high | | Natesto | Intranasal | <1% | Minimal | | Testosterone cypionate IM | Intramuscular | <1% | No | | Testosterone enanthate IM | Intramuscular | <1% | No | | Testosterone cypionate SQ | Subcutaneous | <1% | No | | Testopel pellets | Subcutaneous | ~2% | No | | Aveed (undecanoate IM) | Intramuscular | ~2.3% | No | | Jatenzo (undecanoate oral) | Oral (lymphatic) | ~3% | Low | | Clomiphene citrate | Oral (endogenous) | <1% | Physiologic |

How Long Does Acne From AndroGel Last?

Acne typically begins within 4 to 12 weeks of starting or dose-escalating AndroGel and persists as long as the hormonal stimulus continues. Stopping gel or switching to an injection-based formulation usually produces visible improvement within 4 to 8 weeks as local skin DHT normalizes. Patients with pre-existing comedonal acne or those who developed cystic lesions may need additional dermatologic therapy for 12 to 24 weeks after the formulation switch before full resolution.

The Endocrine Society 2018 guideline states: "Testosterone-related acne and oily skin should be managed by dose reduction, and if a change of formulation does not eliminate the problem, referral to a dermatologist is appropriate." (academic.oup.com/jcem)

Monitoring Recommendations on AndroGel

Standard TRT monitoring per the Endocrine Society 2018 Clinical Practice Guideline recommends evaluating for adverse skin effects at 3 to 6 months after initiation and annually thereafter. Practically, patients prone to acne benefit from more frequent check-ins.

Serum Markers to Track

Check total testosterone, free testosterone (by equilibrium dialysis if possible), and DHT at the 6-week and 3-month marks. DHT >1,000 pg/mL on a transdermal formulation is a flag for high local conversion and warrants dose reduction or route change. Some practitioners also check sex hormone-binding globulin (SHBG) because low SHBG raises free testosterone and amplifies androgen-receptor stimulation at the skin.

Skin Self-Assessment Protocol

Patients should photograph affected areas (face, back, chest) at baseline, 6 weeks, and 12 weeks. A validated tool such as the Investigator Global Assessment (IGA) scale allows consistent grading. Any jump from grade 1 (comedonal) to grade 2 (papulopustular) warrants a prescriber call before progression to grade 3 (nodular).